Key facts
- This page summarizes Scott Kellen's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2024, 16:59.
Scott Kellen - 01 Jun 2024 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)
- Reporting relationship
- CFO and Secretary
- Issuer ticker
- DMAC
- Reported as of
- 01 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2024, 16:59:09 UTC
- Prior SEC filing
- 26 Jun 2023
- Next SEC filing
- 03 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy E. Culbert, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott Kellen filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 03 Jun 2024.
Change
- Previous filing in this sequence was filed on 26 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DMAC
holding
Voting Common Shares, no par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 32,290
- Date
- 01 Jun 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DMAC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +130,000
- Change %
- Price
- $0.000000
- Shares after
- 130,000
- Date
- 01 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 130,000
- Exercise price
- $2.90
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025.